Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives Average Rating of “Hold” from Analysts

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has earned an average rating of “Hold” from the seven research firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $3.75.

A number of analysts recently issued reports on HOWL shares. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th.

Insider Buying and Selling

In other Werewolf Therapeutics news, major shareholder Ra Capital Management, L.P. sold 101,151 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $0.64, for a total transaction of $64,736.64. Following the transaction, the insider owned 406,282 shares of the company’s stock, valued at $260,020.48. This trade represents a 19.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Luke Evnin sold 80,852 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $0.48, for a total transaction of $38,808.96. Following the transaction, the director directly owned 682,833 shares in the company, valued at approximately $327,759.84. This represents a 10.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 2,057,769 shares of company stock worth $1,317,074. 23.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently bought and sold shares of the stock. Regal Investment Advisors LLC raised its stake in Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the period. Vontobel Holding Ltd. raised its stake in shares of Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock valued at $38,000 after acquiring an additional 24,003 shares during the period. Qube Research & Technologies Ltd purchased a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $48,000. AQR Capital Management LLC purchased a new position in shares of Werewolf Therapeutics in the 1st quarter valued at $79,000. Finally, Bridgeway Capital Management LLC raised its stake in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock valued at $111,000 after acquiring an additional 62,414 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Price Performance

HOWL stock opened at $0.47 on Thursday. The company’s 50 day simple moving average is $0.74 and its 200-day simple moving average is $0.75. The firm has a market capitalization of $22.65 million, a PE ratio of -0.38 and a beta of 0.29. Werewolf Therapeutics has a 12 month low of $0.40 and a 12 month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. As a group, sell-side analysts anticipate that Werewolf Therapeutics will post -1.29 earnings per share for the current year.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.